Stevens Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Stevens Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,190	Closed	-$56K	–	839
2018 Q2	$56K	Buy	+1,190	New	+$65.6K	﹤0.01%	749
2016 Q2	–	Sell	-845	Closed	-$88K	–	1001
2016 Q1	$88K	Sell	845 -2,816	-77%	-$217K	﹤0.01%	832
2015 Q4	$295K	Buy	+3,661	New	+$291K	0.01%	700
2015 Q2	–	Sell	-4,460	Closed	-$437K	–	1122
2015 Q1	$437K	Buy	4,460 +1,583	+55%	+$153K	0.02%	619
2014 Q4	$317K	Buy	+2,877	New	+$352K	0.01%	696

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stevens Capital Management's INO Position: Q3 2018 in Review

Stevens Capital Management sold out of Inovio Pharmaceuticals (INO) in Q3 2018, closing a stake of 1,190 shares — an estimated $56K sold.

Stevens Capital Management first reported a position in INO in Q4 2014 and held it in 5 quarters. The position peaked at $437K in Q1 2015. 130 funds tracked by Wall St. Rank hold INO as of Q3 2018.

Stevens Capital Management reported no remaining Inovio Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Stevens Capital Management sold 1,190 Inovio Pharmaceuticals shares in Q3 2018, an estimated $56K.
Stevens Capital Management first reported a position in Inovio Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Stevens Capital Management's Inovio Pharmaceuticals position peaked at $437K in Q1 2015.
130 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2018.

Based on Stevens Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.